ClinicalTrials.gg
CompletedNCT07364838Updated Jan 23, 2026

Study to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers

A Phase 1 interventional study of DW4421 in GERD (Gastroesophageal Reflux Disease), sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Nov 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
43rd of 52
24 · median 54
Started
2024
with 3 others
Phase 1
21 of 71
2 open now
Registered
64th of 71
by date

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 43rd largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2024, is one of 21 in phase 1, and was the 64th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Randomized, Open-label, Oral in healthy volunteers

03

Conditions studied

  • GERD (Gastroesophageal Reflux Disease)
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteers who are ≥19 years old
  • Body weight ≥50.0 kg and between 18.0 and 30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Medical History
  • In the case of women, pregnant(Urine-HCG positive) or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence A

    Cross-over

    Drug: DW4421

  • Experimental
    Sequence B

    Cross-over

    Drug: DW4421

Interventions

  • DrugDW4421

    DW4421 on fasted or fed condition

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Cmax of DW4421

    Time frame: up to 48 hours

  2. Area under the plasma concentration versus time curve (AUC)

    AUC of DW4421

    Time frame: up to 48 hours

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2025, 4 months.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 4 months is close to that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 23, 2026
StartActual
Nov 21, 2024
Primary completionActual
Apr 8, 2025
CompletionActual
Apr 8, 2025
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07364838
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Nov 21, 2024
Primary completion
Apr 8, 2025
Completion
Apr 8, 2025
Last update
Jan 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DW4421

Start the discussion